E.g., 22/10/2020
E.g., 22/10/2020

NucliSens®, miniMAG™, the first product from bioMérieux’s next generation nucleic acid extraction platform now available.

02 April, 2004

Marcy l'Etoile, France - April 2nd, 2004. bioMérieux announces the introduction of NucliSens miniMAG and NucliSens Magnetic Extraction Reagents, two key components of the company’s next generation nucleic acid extraction technology.

“These two products make up a novel...

U.S. FDA Premarket Notification 510(k) Clearance of Polycarbonate BacT/ALERT® Culture Bottles for Microbial QC Testing of Leukocyte-Reduced Single Units of Whole Blood Platelet Concentrates (WBPC)

26 March, 2004

Marcy-l’Etoile, France - March 26, 2004. bioMérieux announces U.S. FDA-CBER (1) Premarket Notification 510(k) clearance of the recently launched, innovative polycarbonate BacT/ALERT BPA and BacT/ALERT BPN culture bottles for microbial quality control testing of leukocyte-reduced single...

bioMérieux launches its first molecular multi-detection test for food and feed analysis : FoodExpert-ID®

24 February, 2004

Marcy l'Etoile, France - February 24th, 2004. bioMérieux announces the launch of FoodExpert-ID, the first high-density DNA chip for food and animal feed testing. The FoodExpert-ID test, powered by Affymetrix® GeneChip® technology, will make it possible to verify the animal species...

bioMérieux signs Clinton Foundation initiative on HIV

14 January, 2004

Marcy l'Etoile, France - January 14th, 2004.

bioMerieux, is a major player in the field of in vitro infectious disease diagnostics. Founded in 1963 in France, the company designs, develops, manufactures and markets reagents and automated instruments for medical analyses. Today,more...

bioMérieux receives CE Mark certification for IVD products maketed in the European Union

08 January, 2004

Marcy l'Etoile, France - January 8th, 2004. bioMérieux has received CE Mark certifications for all of its in vitro diagnostic (IVD) products currently marketed in the European Union (EU). In compliance with the requirements of the 98/79/EC directive for CE Marking, which became applicable on...

Cepheid and bioMérieux enter into strategic commercial program

06 January, 2004

Cepheid (NASDAQ: CPHD) today announced that it has entered into a strategic commercial relationship with bioMerieux for bioMerieux to develop DNA testing products embodying its proprietary NASBA (Nucleic Acid Sequence-Based Amplification) technology to be run on...